

AMENDMENTS TO THE SPECIFICATION

Amend the paragraph at p. 7, lines 11-19, as follows:

Sterile formulations of the IGD peptides as specified in SEQ 10 NOS. 1-6 may prepared by synthesizing the peptides in a peptide synthesizer and filter sterilizing the resulting solutions using a 0.22 micron filter. The peptides can be lyophilized following the filter sterilization and reconstituted in 1% aqueous polyvinylpyrrolidinone or other povidone compounds as described in co-pending U.S. patent Application Serial No. 10/027,669 , filed ~~concurrently~~ herewith December 21, 2001, entitled **"POVIDONE-CONTAINING CARRIERS FOR POLYPEPTIDE GROWTH FACTORS,"** which is hereby incorporated herein in its entirety. Alternatively, other known carriers such as dilute HCl (10 mmol) may be used. Povidone is preferred as a carrier in conducting in vitro assays because it is not cytotoxic.

Amend the paragraph at p. 7, lines 21-25, as follows:

The ability of IGD-motif peptides according to the present invention to promote cell migration of human endothelial and smooth muscle cells, which are processes characteristic of angiogenesis, was evaluated by conducting cell migration assays for the peptides of SEQ 10 NOS 1 and 2, and a scramble of the IGD peptide characterized by the DIG sequence. A capped version of the ~~serample~~ scramble characterized by the GGDIGGG (SEQ ID NO:7) sequence was also tested.